MXCT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

9.30M

+6.96%

-0.080

-20%

8.84M

-14.92%

-0.060

-40%

8.93M

+4.96%

-0.060

-50%

Estimates Revision

The market is revising Downward the revenue expectations for MaxCyte, Inc. (MXCT) for FY2025, with the revenue forecasts being adjusted by -2.73% over the past three months. During the same period, the stock price has changed by -7.14%.

Revenue Estimates for FY2025

Revise Downward

-2.73%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.7%

In Past 3 Month

Stock Price

Go Down

-7.14%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast MXCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MXCT is 6.92 USD with a low forecast of 4.94 USD and a high forecast of 8.89 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.94

Averages

6.92

High

8.89

Current: 0.000

Low

4.94

Averages

6.92

High

8.89

BTIG

Buy

Neutral

downgrade

2025-08-11

Reason

BTIG

Price Target

2025-08-11

downgrade

Buy

Neutral

Reason

BTIG downgraded MaxCyte to Neutral from Buy without a price target after \"a tough Q2 business update\" and lowering of the bar for 2025. MaxCyte lowered its 2025 revenue guide by $5M, or 14% of its business, citing ongoing challenges for many of its cell and gene therapy customers to obtain capital to fund programs, purchase capital, or lease its systems, the analyst noted. The firm thinks the company still has a best-in-class electroporation platform, arguing that the \"number one driver to turn the business around is simply its customers becoming more readily able to raise money and invest in more programs.\"

William Blair

Matt Larew

Outperform -> Market Perform

downgrade

2025-08-07

Reason

William Blair

Matt Larew

Price Target

2025-08-07

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Matt Larew downgraded MaxCyte to Market Perform from Outperform following the earnings report. The company reported a miss and guidance reduction in a strong bioprocessing tools tape, the analyst tells investors in a research note. The firm attributes the miss to MaxCyte's customer exposure and less visible revenue profile. William Blair believes the company's visibility seems lower than peers.

Stephens

Overweight

initiated

2025-07-21

Reason

Stephens

Price Target

2025-07-21

initiated

Overweight

Reason

Stephens initiated coverage of MaxCyte with an Overweight rating and $6 price target. The company is in the early stages of making prudent investments in offerings that expand its reach of the market, the analyst tells investors in a research note. The firm added that while this strategy is still in the early innings, it believe the strategy has the potential to drive long-term revenue growth.

Stifel

Daniel Arias

Strong Buy

Maintains

$11 → $9

2025-03-12

Reason

Stifel

Daniel Arias

Price Target

$11 → $9

2025-03-12

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on MaxCyte to $9 from $11 and keeps a Buy rating on the shares. Management's guidance for 2025 positions core revenues as up 8%-15%, notes the analyst, who adds that there "does appear to be upside potential to the guide," most notably from an embedded assumption that end markets do not improve. The firm continues to like MaxCyte as a play on what should be a rebound year for cell therapy, but "the pace at which the thesis plays out could be on the slower side," the analyst added.

Valuation Metrics

The current forward P/E ratio for MaxCyte Inc (MXCT.O) is -6.04, compared to its 5-year average forward P/E of -16.45. For a more detailed relative valuation and DCF analysis to assess MaxCyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-16.45

Current PE

-6.04

Overvalued PE

-0.84

Undervalued PE

-32.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-16.71

Current EV/EBITDA

-3.27

Overvalued EV/EBITDA

7.88

Undervalued EV/EBITDA

-41.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

12.35

Current PS

4.49

Overvalued PS

20.18

Undervalued PS

4.52

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MXCT News & Events

Events Timeline

No data

News

5.0

2025-12-01Newsfilter

Cellares Appoints New CCO to Support 2026 Clinical Trials

4.5

2025-09-22Newsfilter

MaxCyte Unveils Operational Restructuring Aimed at Cost Reduction and Faster Profitability

4.0

2025-08-11Benzinga

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

People Also Watch

Frequently Asked Questions

What is MaxCyte Inc (MXCT) stock price today?

The current price of MXCT is 1.43 USD — it has decreased -2.72 % in the last trading day.

What is MaxCyte Inc (MXCT)'s business?

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

What is the price predicton of MXCT Stock?

What is MaxCyte Inc (MXCT)'s revenue for the last quarter?

MaxCyte Inc revenue for the last quarter amounts to 6.83M USD, decreased -16.35 % YoY.

What is MaxCyte Inc (MXCT)'s earnings per share (EPS) for the last quarter?

MaxCyte Inc. EPS for the last quarter amounts to -0.12 USD, increased 9.09 % YoY.

What changes have occurred in the market's expectations for MaxCyte Inc (MXCT)'s fundamentals?

How many employees does MaxCyte Inc (MXCT). have?

MaxCyte Inc (MXCT) has 114 emplpoyees as of January 10 2026.

What is MaxCyte Inc (MXCT) market cap?

Today MXCT has the market capitalization of 152.54M USD.